A Two-part, Phase I/IIA dose Excalation Study to Define the Safety, Tolerability, and optimal Dose of candidate GBM vaccine VBI-1901 with Subsequent Extension of Optimal Dose in Recurrent GBM Subjects

Protocol: 
AAAR5300
Phase: 
I/II

A Two-part, Phase I/IIA dose Excalation Study to Define the Safety, Tolerability, and optimal Dose of candidate GBM vaccine VBI-1901 with Subsequent Extension of Optimal Dose in Recurrent GBM Subjects

Are you Eligible? (Inclusion Criteria)

Participants must:
1. Be 18 - 70 years of age
2. Have histologically confirmed WHO grade IV glioblastoma
3. Have unequivocal evidence of a tumor recurrence (any number of
recurrences) or progression after an initial treatment regimen (prior to
enrollment on this study)
4. Have recovered from the effects of surgery

Specialty Area(s)

Immunotherapy

Trial Location

Herbert Irving Comprehensive Cancer Center
161 Fort Washington Ave.
Herbert Irving Pavilion
New York, NY 10032
United States